Fragile X Syndrome Market Share, Growth, Pipeline
Review, H1 2016 by Radiant Insights
Summary
Global Markets Direct's, ‘Fragile X Syndrome - Pipeline Review, H1 2016', provides an overview of the
Fragile X Syndrome pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Fragile X
Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological
action of the therapeutics, its complete research and development history and latest news and press
releases. Additionally, the report provides an overview of key players involved in therapeutic
development for Fragile X Syndrome and features dormant and discontinued projects.
Browse Ongoing Reports @ http://www.radiantinsights.com/research/fragile-x-syndrome-pipelinereview-h1-2016
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Markets Direct's proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic
review following a stringent set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective counter strategies to gain
competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance
of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Fragile X Syndrome
- The report reviews pipeline therapeutics for Fragile X Syndrome by companies and
universities/research institutes based on information derived from company and industry-specific
sources
- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product
description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental
activities
- The report reviews key players involved Fragile X Syndrome therapeutics and enlists all their major and
minor projects
- The report assesses Fragile X Syndrome therapeutics based on drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Fragile X Syndrome
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D
strategies
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Fragile X
Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline
therapeutics
- Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth
and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors
that drove them from pipeline
Browse More Categories @ http://www.radiantinsights.com/catalogs
Table of Content
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Fragile X Syndrome Overview 9
Therapeutics Development 10
Pipeline Products for Fragile X Syndrome - Overview 10
Pipeline Products for Fragile X Syndrome - Comparative Analysis 11
Fragile X Syndrome - Therapeutics under Development by Companies 12
Fragile X Syndrome - Therapeutics under Investigation by Universities/Institutes 13
Fragile X Syndrome - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Fragile X Syndrome - Products under Development by Companies 16
Fragile X Syndrome - Products under Investigation by Universities/Institutes 17
Fragile X Syndrome - Companies Involved in Therapeutics Development 18
Aelis Farma SAS 18
Alcobra Ltd 19
AMO Pharma Limited 20
Confluence Pharmaceuticals LLC 21
Eli Lilly and Company 22
F. Hoffmann-La Roche Ltd. 23
Marinus Pharmaceuticals, Inc. 24
MI.TO. Technology S.r.L. 25
Neuren Pharmaceuticals Limited 26
Ovid Therapeutics Inc. 27
Sage Therapeutics, Inc. 28
Zynerba Pharmaceuticals, Inc. 29
Fragile X Syndrome - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Browse Ongoing Reports @ http://www.radiantinsights.com/research/fragile-x-syndrome-pipelinereview-h1-2016
About Us:
Radiant Insights Inc. is a platform for companies looking to meet their market research and business
intelligence requirements. We assist and facilitate organizations and individuals procure market
research reports, helping them in the decision making process. We have a comprehensive collection of
reports, covering over 40 key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of ancillary services such
as, research partnerships/ tie-ups and customized research solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street,
Suite 3036 San Francisco,
CA 94105 United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Website: http://www.radiantinsights.com/
Email: [email protected]
Visit our Blog: http://chemicalsandmaterialsri.blogspot.com/

The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Read More @ http://www.radiantinsights.com/research/fragile-x-syndrome-pipeline-review-h1-2016